SN
SNW.XETRA Sanofi
- Market cap
- EUR 98.1B
- P/E
- 23.7x
- P/B
- 1.38x
- ROE
- 9.1%
- Dividend yield
- 4.87%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is SNW.XETRA undervalued?
Graham numberSNW.XETRA trades 20.6% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Sanofi fundamental analysis
No fundamental analysis for Sanofi yet.
Sanofi stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Sanofi
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions in Finland and Germany. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection; hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines; and Fluzone, a flu…
Full company profileSanofi financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Sanofi annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 34.7B | 36.2B | 35.7B | 37.6B | 37.4B | 39.2B | 43.0B | 46.0B | 44.3B | 43.6B | 51.7B |
| Gross Profit | 24.0B | 24.6B | 24.2B | 25.7B | 25.2B | 26.9B | 31.7B | 31.8B | 31.1B | 28.7B | 38.7B |
| Operating Income | 6.53B | 5.80B | 4.68B | 3.05B | 14.1B | 8.13B | 10.2B | 6.96B | 7.25B | 6.34B | 12.5B |
| EBITDA | 9.05B | 9.03B | 8.34B | 7.11B | 17.5B | 11.3B | 14.1B | 12.0B | 11.0B | 15.3B | 15.6B |
| Net Income | 4.71B | 8.43B | 4.31B | 2.75B | 12.3B | 6.22B | 8.37B | 5.40B | 5.56B | 7.81B | 6.64B |
| EPS | 3.66 | 6.71 | 3.45 | 2.19 | 9.76 | 4.95 | 6.66 | 4.30 | 4.44 | 6.37 | 5.54 |
| Balance Sheet | |||||||||||
| Total Assets | 105B | 99.8B | 111B | 113B | 115B | 120B | 125B | 126B | 133B | 127B | 130B |
| Total Liabilities | 46.9B | 41.6B | 52.4B | 53.6B | 51.4B | 51.2B | 51.1B | 52.1B | 54.9B | 55.1B | 57.0B |
| Shareholders' Equity | 57.6B | 58.1B | 58.9B | 58.9B | 63.0B | 68.7B | 74.8B | 74.0B | 77.5B | 71.4B | 72.9B |
| Cash & Short-term Investments | 10.3B | 10.3B | 6.93B | 9.43B | 13.9B | 10.1B | 12.7B | 8.71B | 7.93B | 7.66B | 5.97B |
| Total Debt | 18.6B | 15.6B | 24.7B | 26.0B | 23.7B | 22.4B | 21.2B | 18.4B | 17.9B | 20.3B | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 8.18B | 7.38B | 5.55B | 7.74B | 7.45B | 10.5B | 10.5B | 10.3B | 9.08B | 10.8B | 13.6B |
| Capital Expenditure | 2.08B | 1.96B | 1.98B | 1.82B | 2.11B | 2.04B | 2.20B | 1.62B | 3.20B | 1.76B | 1.73B |
| Free Cash Flow | 5.76B | 5.42B | 3.57B | 5.93B | 5.34B | 8.48B | 8.33B | 8.64B | 5.89B | 8.99B | 13.6B |
| Ratios | |||||||||||
| ROE | 8.2% | 14.5% | 7.3% | 4.7% | 19.5% | 9.1% | 11.2% | 7.3% | 7.2% | 10.9% | 9.1% |
| ROA | 4.5% | 8.4% | 3.9% | 2.4% | 10.7% | 5.2% | 6.7% | 4.3% | 4.2% | 6.2% | 5.1% |
| Net Profit Margin | 13.6% | 23.3% | 12.1% | 7.3% | 32.9% | 15.9% | 19.5% | 11.7% | 12.6% | 17.9% | 12.8% |
| Debt to Equity | 0.32x | 0.27x | 0.42x | 0.44x | 0.38x | 0.33x | 0.28x | 0.25x | 0.23x | 0.28x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Sanofi dividends
- Dividend yield
- 4.87%
- Forward dividend
- 4.12 EUR
- Payout ratio
- 61.1%
- Ex-dividend date
- May 5, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | EUR 4.77B | 3.89 | 61.1% |
| 2024 | EUR 4.70B | 3.76 | 84.6% |
| 2023 | EUR 4.45B | 3.55 | 82.5% |
| 2022 | EUR 4.17B | 3.32 | 49.8% |
| 2021 | EUR 4.01B | 3.19 | 64.4% |
| 2020 | EUR 3.94B | 3.12 | 32.0% |
| 2019 | EUR 3.83B | 3.05 | 139.2% |
| 2018 | EUR 3.77B | 3.03 | 87.6% |
| 2017 | EUR 3.71B | 2.95 | 44.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Sanofi
- Insiders 10.31%
- Institutions 41.81%
- Public & others 47.88%
- Shares outstanding 1.20B
- Free float 1.08B
Sanofi company profile
- Company name
- Sanofi
- Ticker
- SNW.XETRA
- ISIN
- FR0000120578
- Exchange
- XETRA Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 74,846
- Fiscal year end
- December
- Address
- 46, avenue de la Grande ArmEe, Paris, France, 75017
- Phone
- 33 1 53 77 40 00
- Website
- sanofi.com
About Sanofi
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions in Finland and Germany. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection; hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines; and Fluzone, a flu vaccine. It has a collaboration and license agreement with Exscientia to develop small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine's AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV'574, for treatment of ulcerative colitis and Crohn's disease; co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab; and antibody collaboration with Regeneron Pharmaceuticals, Inc. to develop antibodies, such as Dupixent (dupilumab) as treatment for diseases driven by type 2 inflammation. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
Sanofi management
10- Ms. Belen Garijo Lopez M.D.CEO & Director · born 1960
- Mr. François-Xavier RogerExecutive VP & CFO · born 1962
- Dr. Michael Quigley Ph.D.Chief Scientific Officer & Head of Research
- Mr. Thomas Kudsk LarsenHead of Investor Relations & General Medicines · born 1974
- Ms. Jamie HaneyExecutive VP & General Counsel
- Mr. Pierre ChancelSenior Vice President of Global Diabetes and Senior Vice President of Global Marketing · born 1957
- Ms. Veronique JailletExecutive VP & Interim Chief People Officer
- Fabrizio GaudiHead of Austrian, German & Swiss Operations
- Mr. Erik WallströmHead of Therapeutic Area - Neurology Development
- Mr. Thomas TriompheExecutive Vice President of Vaccines · born 1974